Abstract 1622: Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Zhiyuan Chen(Wuhan University), Rong Guo(Sun Yat-sen University), Ming Shi(Yanshan University), Wei Wei(Zhujiang Hospital), Xinjian Li(Chinese Academy of Sciences), Shuhong Li(Yunnan Academy of Agricultural Sciences), Zhixing Guo(Sun Yat-sen University), Chao‐Nan Qian(South China Agricultural University), Li‐Xia Peng(Sun Yat-sen University), Chong Zhong(Guangzhou University of Chinese Medicine)
Cited by 0
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy
|Molecular Cell|2017|282
DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis
|Nature Communications|2021|232
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216